Persistence of secondary prevention medications after acute ischemic stroke or transient ischemic attack in Chinese population: Data from China National Stroke Registry

Neurological Research

Volumn 35, Issue 1, 2013, Pages 29-36

  Ji, Ruijun ^a,b   Liu, Gaifen ^a   Shen, Haipeng ^b   Wang, Yilong ^a   Li, Hao ^a   Peterson, Eric ^c   Wang, Yongjun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute ischemic stroke; Medication; Outcomes; Persistence; Related factors; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; WARFARIN;

ADULT; AGED; ARTICLE; CHINESE; FEMALE; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANKIN SCALE; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; AGED; CHINA; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; STATISTICS, NONPARAMETRIC; STROKE; YOUNG ADULT;

EID: 84872533947     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000107     Document Type: Article

References (26)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-209.
2. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328:326.
3. Coutts SB, Hill MD, Simon JE, Sohn CH, Scott JN, Demchuk AM, et al. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology. 2005;65:513-7.
4. Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16:280-5.
5. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
6. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238- 51.
7. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39:1647-52.
8. Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 2012;33:199- 208.
9. Rother J, Crijns H. Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. Cerebrovasc Dis. 2010;30:314-22.
10. Rahiman A, Saver JL, Porter V, Buxton W, McNair N, Razinia T, et al. In-hospital initiation of secondary prevention is associated with improved vascular outcomes at 3 months. J Stroke Cerebrovasc Dis. 2008;17:5-8.
11. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, et al. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke. 2004;35:2879-83.
12. Ovbiagele B, Campbell S, Faiz A, Chambless LE; VISP Study Investigators. Relationship between non-specific prescription pill adherence and ischemic stroke outcomes. Cerebrovasc Dis. 2010;29:146-53.
13. Touzé E, Coste J, Voicu M, Kansao J, Masmoudi R, Doumenc B, et al. Importance of in-hospital initiation of therapies and therapeutic inertia in secondary stroke prevention: IMplementation of Prevention After a Cerebrovascular evenT (IMPACT) Study. Stroke. 2008;39:1834-43.
14. Bushnell CD, Zimmer LO, Pan W, Olson DM, Zhao X, Meteleva T, et al. Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol. 2010;67: 1456-63.
15. Bushnell CD, Olson DM, Zhao X, Pan W, Zimmer LO, Goldstein LB, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011;77: 1182-90.
16. Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, et al. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke. 2011;6:355-61.
17. Stroke-1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke. 1989;20:1407-31.
18. Wang Y, Wu D, Wang Y, Ma R, Wang C, Zhao W. A survey on adherence to secondary ischemic stroke prevention. Neurol Res. 2006;28:16-20.
19. Wang Y, Wu D, Zhou Y, Zhao X, Wang C, Liu L, et al. Survey of blood pressure control status in patients with ischemic stroke or transient ischemic attack in China. Neurol Res. 2008;30:348- 55.
20. Wei JW, Wang JG, Huang Y, Liu M, Wu Y, Wong LK, et al. Secondary prevention of ischemic stroke in urban China. Stroke. 2010;41:967-74.
21. Bushnell C, Zimmer L, Schwamm L, Goldstein LB, Clapp-Channing N, Harding T, et al. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics. Am Heart J. 2009;157:428-35.e2.
22. Hillen T, Dundas R, Lawrence E, Stewart JA, Rudd AG, Wolfe CD. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke. 2000;31:469-75.
23. Mouradian MS, Majumdar SR, Senthilselvan A, Khan K, Shuaib A. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack? Stroke. 2002;33:1656-9.
24. Flynn RW, MacDonald TM, Murray GD, MacWalter RS, Doney AS. Persistence, adherence and outcomes with antiplatelet regimens following cerebral infarction in the Tayside Stroke Cohort. Cerebrovasc Dis. 2010;33:190-7.
25. Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397-401.
26. Pit SW, Byles JE, Cockburn J. Accuracy of telephone selfreport of drug use in older people and agreement with pharmaceutical claims data. Drugs Aging. 2008;25:71-80.